This profile makes BPC-157 more difficult to interpret than peptides whose experimental readouts are directly linked to receptor occupancy or a defined receptor-to-pathway cascade
Testing should be performed for patients with the following tumour types: Tumour types known to frequently harbour NTRK gene fusions (i.e., infantile fibrosarcoma, congenital mesoblastic nephroma, mammary analogue secretory carcinoma, and secretory breast cancer) Commonly diagnosed tumour types (e.g., lung cancer and colorectal cancer) known to be negative for other oncogenic alterations through exclusionary testing Colorectal cancer patients with MSI-H/dMMR status Thyroid cancer, salivary cancer, and sarcoma patients Eligibility criteria includes patients with solid tumours that are metastatic, or when surgical resection is likely to result in severe morbidity, and for whom no satisfactory treatment options are available
To further test whether the incorporation of a targeting motif could enhance the binding of chimeric peptides in vivo , we used smearing FITC-peptides at the mouse back for 24 h and tracked the peptide location of the skin slices by fluorescent microscopy
Oct 2019;97(10):1223-1241
A retrospective review of intra-articular knee injections found 14 of 16 patients reported significant pain relief
Topical BPC-157 treatment accelerated wound closure following alkali burns in rats
